- Report
- February 2025
- 315 Pages
Global
From €4220EUR$4,799USD£3,679GBP
- Report
- January 2025
- 456 Pages
Global
From €4353EUR$4,950USD£3,794GBP
- Report
- November 2025
- 198 Pages
Global
From €3118EUR$3,545USD£2,718GBP
€3464EUR$3,939USD£3,019GBP
- Report
- November 2025
- 183 Pages
Global
From €3957EUR$4,500USD£3,450GBP
- Report
- December 2025
- 373 Pages
Global
From €5145EUR$5,850USD£4,484GBP
- Report
- December 2025
- 282 Pages
Global
From €5145EUR$5,850USD£4,484GBP
- Report
- September 2025
- 250 Pages
Global
From €3949EUR$4,490USD£3,442GBP
- Report
- February 2025
- 200 Pages
Global
From €3949EUR$4,490USD£3,442GBP
- Report
- June 2025
- 400 Pages
Global
From €4352EUR$4,949USD£3,794GBP
- Report
- April 2025
- 125 Pages
United States
From €2858EUR$3,250USD£2,491GBP
- Report
- January 2024
- 200 Pages
Global
From €3650EUR$4,150USD£3,181GBP
- Book
- August 2021
- 312 Pages
- Book
- January 2024
North America
Hepatocellular Carcinoma (HCC) is a type of cancer that originates in the liver. It is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. HCC is typically diagnosed in individuals with underlying liver diseases such as cirrhosis, hepatitis B or C, and non-alcoholic fatty liver disease. Treatment options for HCC include surgery, radiation therapy, chemotherapy, and targeted therapy.
The oncology market for HCC is highly competitive, with a number of companies offering treatments and therapies. These include AbbVie, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche, and Takeda. Additionally, there are a number of smaller companies that are developing novel therapies for HCC, such as Aduro Biotech, ArQule, and Oncoceutics. Show Less Read more
